{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:37:14Z","timestamp":1793165834240,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA042014"],"award-info":[{"award-number":["P30-CA042014"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA042014"],"award-info":[{"award-number":["P30-CA042014"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA039145"],"award-info":[{"award-number":["DA039145"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA031833"],"award-info":[{"award-number":["DA031833"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA039145"],"award-info":[{"award-number":["DA039145"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"U.S. Department of Health & Human Services | NIH | National Center for Research Resources","doi-asserted-by":"publisher","award":["CA042014"],"award-info":[{"award-number":["CA042014"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"U.S. Department of Health & Human Services | NIH | National Center for Research Resources","doi-asserted-by":"publisher","award":["RR021746"],"award-info":[{"award-number":["RR021746"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41386-018-0207-5","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T20:43:29Z","timestamp":1536698609000},"page":"2548-2555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit\/hyperactivity disorder"],"prefix":"10.1038","volume":"43","author":[{"given":"Karen","family":"Curtin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette E.","family":"Fleckenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooks R.","family":"Keeshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Yurgelun-Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry F.","family":"Renshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen R.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,12]]},"reference":[{"key":"207_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/mp.2016.74","volume":"21","author":"C Bonvicini","year":"2016","unstructured":"Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry. 2016;21:872\u201384.","journal-title":"Mol Psychiatry"},{"key":"207_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","volume":"194","author":"V Simon","year":"2009","unstructured":"Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204\u201311.","journal-title":"Br J Psychiatry"},{"key":"207_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S2215-0366(16)30032-3","volume":"3","author":"P Asherson","year":"2016","unstructured":"Asherson P, Buitelaar J, Faraone SV, Rohde LA. Adult attention-deficit hyperactivity disorder: key conceptual issues. Lancet Psychiatry. 2016;3:568\u201378.","journal-title":"Lancet Psychiatry"},{"key":"207_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.15585\/mmwr.mm6517e1","volume":"65","author":"SN Visser","year":"2016","unstructured":"Visser SN, Danielson ML, Wolraich ML, Fox MH, Grosse SD, Valle LA, et al. Vital Signs: National and State-Specific Patterns of Attention Deficit\/Hyperactivity Disorder Treatment Among Insured Children Aged 2\u20135 Years\u2014United States, 2008\u20132014. MMWR Morb Mortal Wkly Rep. 2016;65:443\u201350.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"207_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.lfs.2013.07.014","volume":"97","author":"LE Halpin","year":"2014","unstructured":"Halpin LE, Collins SA, Yamamoto BK. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci. 2014;97:37\u201344.","journal-title":"Life Sci"},{"key":"207_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/syn.20471","volume":"62","author":"UD McCann","year":"2008","unstructured":"McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse. 2008;62:91\u2013100.","journal-title":"Synapse"},{"key":"207_CR7","doi-asserted-by":"publisher","first-page":"8417","DOI":"10.1523\/JNEUROSCI.18-20-08417.1998","volume":"18","author":"UD McCann","year":"1998","unstructured":"McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 1998;18:8417\u201322.","journal-title":"J Neurosci"},{"key":"207_CR8","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1176\/appi.ajp.158.8.1206","volume":"158","author":"Y Sekine","year":"2001","unstructured":"Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001;158:1206\u201314.","journal-title":"Am J Psychiatry"},{"key":"207_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nm0696-699","volume":"2","author":"JM Wilson","year":"1996","unstructured":"Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 1996;2:699\u2013703.","journal-title":"Nat Med"},{"key":"207_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/mds.22915","volume":"25","author":"CW Christine","year":"2010","unstructured":"Christine CW, Garwood ER, Schrock LE, Austin DE, McCulloch CE. Parkinsonism in patients with a history of amphetamine exposure. Mov Disord. 2010;25:228\u201331.","journal-title":"Mov Disord"},{"key":"207_CR11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.neuro.2006.03.015","volume":"27","author":"ER Garwood","year":"2006","unstructured":"Garwood ER, Bekele W, McCulloch CE, Christine CW. Amphetamine exposure is elevated in Parkinson\u2019s disease. Neurotoxicology. 2006;27:1003\u20136.","journal-title":"Neurotoxicology"},{"key":"207_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.pneurobio.2015.09.011","volume":"155","author":"R Moratalla","year":"2017","unstructured":"Moratalla R, Khairnar A, Simola N, Granado N, Garcia-Montes JR, Porceddu PF, et al. Amphetamine-related drugs neurotoxicity in humans and in experimental animals: main mechanisms. Prog Neurobiol. 2017;155:149\u201370.","journal-title":"Prog Neurobiol"},{"key":"207_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drugalcdep.2014.10.027","volume":"146","author":"K Curtin","year":"2015","unstructured":"Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine\/amphetamine abuse and risk of Parkinson\u2019s disease in Utah: a population-based assessment. Drug Alcohol Depend. 2015;146:30\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"207_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1017\/S1461145709990198","volume":"12","author":"A Meszaros","year":"2009","unstructured":"Meszaros A, Czobor P, Balint S, Komlosi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol. 2009;12:1137\u201347.","journal-title":"Int J Neuropsychopharmacol"},{"key":"207_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jaac.2013.09.001","volume":"53","author":"SN Visser","year":"2014","unstructured":"Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit\/hyperactivity disorder: United States, 2003\u20132011. J Am Acad Child Adolesc Psychiatry. 2014;53:34\u201346 e32.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"207_CR16","first-page":"890","volume":"85","author":"RE Post","year":"2012","unstructured":"Post RE, Kurlansik SL. Diagnosis and management of adult attention-deficit\/hyperactivity disorder. Am Fam Physician. 2012;85:890\u20136.","journal-title":"Am Fam Physician"},{"key":"207_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10567-014-0177-z","volume":"18","author":"K Benson","year":"2015","unstructured":"Benson K, Flory K, Humphreys KL, Lee SS. Misuse of stimulant medication among college students: a comprehensive review and meta-analysis. Clin Child Fam Psychol Rev. 2015;18:50\u201376.","journal-title":"Clin Child Fam Psychol Rev"},{"key":"207_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.parkreldis.2012.09.014","volume":"19","author":"AW Willis","year":"2013","unstructured":"Willis AW, Schootman M, Kung N, Racette BA. Epidemiology and neuropsychiatric manifestations of Young Onset Parkinson\u2019s Disease in the United States. Park Relat Disord. 2013;19:202\u20136.","journal-title":"Park Relat Disord"},{"key":"207_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.parkreldis.2004.03.001","volume":"10","author":"W Tse","year":"2004","unstructured":"Tse W, Cersosimo MG, Gracies JM, Morgello S, Olanow CW, Koller W. Movement disorders and AIDS: a review. Park Relat Disord. 2004;10:323\u201334.","journal-title":"Park Relat Disord"},{"key":"207_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.drugalcdep.2011.06.013","volume":"120","author":"RC Callaghan","year":"2012","unstructured":"Callaghan RC, Cunningham JK, Sykes J, Kish SJ. Increased risk of Parkinson\u2019s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend. 2012;120:35\u201340.","journal-title":"Drug Alcohol Depend"},{"key":"207_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.drugalcdep.2008.01.021","volume":"96","author":"ML Brecht","year":"2008","unstructured":"Brecht ML, Huang D, Evans E, Hser YI. Polydrug use and implications for longitudinal research: ten-year trajectories for heroin, cocaine, and methamphetamine users. Drug Alcohol Depend. 2008;96:193\u2013201.","journal-title":"Drug Alcohol Depend"},{"key":"207_CR22","first-page":"425","volume":"5","author":"SS Bettiol","year":"2015","unstructured":"Bettiol SS, Rose TC, Hughes CJ, Smith LA. Alcohol consumption and Parkinson\u2019s disease risk: a review of recent findings. J Park Dis. 2015;5:425\u201342.","journal-title":"J Park Dis"},{"key":"207_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/ana.10611","volume":"54","author":"MA Hernan","year":"2003","unstructured":"Hernan MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson\u2019s disease. Ann Neurol. 2003;54:170\u20135.","journal-title":"Ann Neurol"},{"key":"207_CR24","doi-asserted-by":"publisher","first-page":"e66452","DOI":"10.1371\/journal.pone.0066452","volume":"8","author":"R Liu","year":"2013","unstructured":"Liu R, Guo X, Park Y, Wang J, Huang X, Hollenbeck A, et al. Alcohol consumption, types of alcohol, and Parkinson\u2019s disease. PLoS ONE. 2013;8:e66452.","journal-title":"PLoS ONE"},{"key":"207_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1474-4422(06)70411-2","volume":"5","author":"A Schrag","year":"2006","unstructured":"Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006;5:355\u201363.","journal-title":"Lancet Neurol"},{"key":"207_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S1071-9091(02)00011-6","volume":"10","author":"EY Uc","year":"2003","unstructured":"Uc EY, Rodnitzky RL. Juvenile parkinsonism. Semin Pediatr Neurol. 2003;10:62\u20137.","journal-title":"Semin Pediatr Neurol"},{"key":"207_CR27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/0-387-29150-4","volume-title":"Competing risks survival analysis","author":"DGKM Kleinbaum","year":"2005","unstructured":"Kleinbaum DG, Klein M. Competing risks survival analysis. New York, NY: Springer; 2005. p. 391\u2013461."},{"key":"207_CR28","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/S0140-6736(14)61684-6","volume":"385","author":"S Dalsgaard","year":"2015","unstructured":"Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385:2190\u20136.","journal-title":"Lancet"},{"key":"207_CR29","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","volume":"383","author":"OD Howes","year":"2014","unstructured":"Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383:1677\u201387.","journal-title":"Lancet"},{"key":"207_CR30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.10277","volume":"52","author":"MA Hernan","year":"2002","unstructured":"Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson\u2019s disease. Ann Neurol. 2002;52:276\u201384.","journal-title":"Ann Neurol"},{"key":"207_CR31","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"K Wirdefeldt","year":"2011","unstructured":"Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson\u2019s disease: a review of the evidence. Eur J Epidemiol. 2011;26:S1\u201358.","journal-title":"Eur J Epidemiol"},{"key":"207_CR32","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1212\/WNL.0000000000000879","volume":"83","author":"B Ritz","year":"2014","unstructured":"Ritz B, Lee PC, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology. 2014;83:1396\u2013402.","journal-title":"Neurology"},{"key":"207_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"HW Shin","year":"2012","unstructured":"Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8:15\u201321.","journal-title":"J Clin Neurol"},{"key":"207_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1124\/jpet.102.045005","volume":"304","author":"V Sandoval","year":"2003","unstructured":"Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther. 2003;304:1181\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"207_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1047-2797(03)00063-2","volume":"13","author":"RM Merrill","year":"2003","unstructured":"Merrill RM, Hilton SC, Daniels M. Impact of the LDS church\u2019s health doctrine on deaths from diseases and conditions associated with cigarette smoking. Ann Epidemiol. 2003;13:704\u201311.","journal-title":"Ann Epidemiol"},{"key":"207_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fnana.2014.00152","volume":"8","author":"L Brichta","year":"2014","unstructured":"Brichta L, Greengard P. Molecular determinants of selective dopaminergic vulnerability in Parkinson\u2019s disease: an update. Front Neuroanat. 2014;8:152.","journal-title":"Front Neuroanat"},{"key":"207_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11065-007-9019-9","volume":"17","author":"JM Swanson","year":"2007","unstructured":"Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, et al. Etiologic subtypes of attention-deficit\/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev. 2007;17:39\u201359.","journal-title":"Neuropsychol Rev"},{"key":"207_CR38","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.biopsych.2010.01.013","volume":"68","author":"K Krauel","year":"2010","unstructured":"Krauel K, Feldhaus HC, Simon A, Rehe C, Glaser M, Flechtner HH, et al. Increased echogenicity of the substantia nigra in children and adolescents with attention-deficit\/hyperactivity disorder. Biol Psychiatry. 2010;68:352\u20138.","journal-title":"Biol Psychiatry"},{"key":"207_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1503\/jpn.090044","volume":"35","author":"M Romanos","year":"2010","unstructured":"Romanos M, Weise D, Schliesser M, Schecklmann M, Loffler J, Warnke A, et al. Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity disorder. J Psychiatry Neurosci. 2010;35:55\u201358.","journal-title":"J Psychiatry Neurosci"},{"key":"207_CR40","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1073\/pnas.98.4.1982","volume":"98","author":"X Zhuang","year":"2001","unstructured":"Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA. 2001;98:1982\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"207_CR41","doi-asserted-by":"publisher","first-page":"13586","DOI":"10.1523\/JNEUROSCI.5069-13.2014","volume":"34","author":"M Subramaniam","year":"2014","unstructured":"Subramaniam M, Althof D, Gispert S, Schwenk J, Auburger G, Kulik A, et al. Mutant alpha-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels. J Neurosci. 2014;34:13586\u201399.","journal-title":"J Neurosci"},{"key":"207_CR42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1474-4422(17)30056-X","volume":"16","author":"DJ Wile","year":"2017","unstructured":"Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E, et al. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol. 2017;16:351\u20139.","journal-title":"Lancet Neurol"},{"key":"207_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12402-017-0219-8","volume":"9","author":"JM Geissler","year":"2017","unstructured":"Geissler JM, International Parkinson Disease Genomics Consortium, Romanos M, Gerlach M, Berg D, Schulte C. No genetic association between attention-deficit\/hyperactivity disorder (ADHD) and Parkinson\u2019s disease in nine ADHD candidate SNPs. Atten Defic Hyperact Disord. 2017;9:121\u20137.","journal-title":"Atten Defic Hyperact Disord"},{"issue":"19","key":"207_CR44","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.2174\/0929867325666171129124616","volume":"25","author":"Geir Bjorklund","year":"2018","unstructured":"Bjorklund G, Stejskal V, Urbina MA, Dadar M, Chirumbolo S, Mutter J. Metals and Parkinson\u2019s disease: mechanisms and biochemical processes. Curr Med Chem. 2018;25:2198\u20132214 (Epub ahead of print).","journal-title":"Current Medicinal Chemistry"},{"key":"207_CR45","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/ana.25074","volume":"82","author":"A Camacho-Soto","year":"2017","unstructured":"Camacho-Soto A, Warden MN, Searles Nielsen S, Salter A, Brody DL, Prather H, et al. Traumatic brain injury in the prodromal period of Parkinson\u2019s disease: a large epidemiological study using medicare data. Ann Neurol. 2017;82:744\u201354.","journal-title":"Ann Neurol"},{"key":"207_CR46","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1038\/npp.2012.127","volume":"37","author":"ND Volkow","year":"2012","unstructured":"Volkow ND. Long-term safety of stimulant use for ADHD: findings from nonhuman primates. Neuropsychopharmacology. 2012;37:2551\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"207_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0006-8993(97)00771-3","volume":"767","author":"J Yuan","year":"1997","unstructured":"Yuan J, McCann U, Ricaurte G. Methylphenidate and brain dopamine neurotoxicity. Brain Res. 1997;767:172\u20135.","journal-title":"Brain Res"},{"key":"207_CR48","doi-asserted-by":"publisher","first-page":"e63023","DOI":"10.1371\/journal.pone.0063023","volume":"8","author":"GJ Wang","year":"2013","unstructured":"Wang GJ, Volkow ND, Wigal T, Kollins SH, Newcorn JH, Telang F, et al. Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. PLoS ONE. 2013;8:e63023.","journal-title":"PLoS ONE"},{"key":"207_CR49","doi-asserted-by":"publisher","first-page":"e33693","DOI":"10.1371\/journal.pone.0033693","volume":"7","author":"S Sadasivan","year":"2012","unstructured":"Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeyne RJ. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS ONE. 2012;7:e33693.","journal-title":"PLoS ONE"},{"key":"207_CR50","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mds.21299","volume":"22","author":"K Noyes","year":"2007","unstructured":"Noyes K, Liu H, Holloway R, Dick AW. Accuracy of Medicare claims data in identifying Parkinsonism cases: comparison with the Medicare current beneficiary survey. Mov Disord. 2007;22:509\u201314.","journal-title":"Mov Disord"},{"key":"207_CR51","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/aje\/kwg068","volume":"157","author":"SK Van Den Eeden","year":"2003","unstructured":"Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity. Am J Epidemiol. 2003;157:1015\u201322.","journal-title":"Am J Epidemiol"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0207-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0207-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0207-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:09Z","timestamp":1684616649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0207-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,12]]},"references-count":51,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["207"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0207-5","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,12]]},"assertion":[{"value":"16 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}